Cabozantinib for Metastatic Triple Negative BrCa
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Dana-Farber Cancer Institute
Related studies linked through entity extraction aliases.
Detecting EGFR T790M Mutations From Circulating Tumor Cells
- Status
- COMPLETED
- Phase
- N/A
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Cisplatin + RT for Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
- Status
- COMPLETED
- Phase
- PHASE2
STA-9090 in Patients With Advanced Hepatocellular Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
- Status
- COMPLETED
- Phase
- NA
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas
- Status
- WITHDRAWN
- Phase
- NA
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Proton or Photon RT for Retroperitoneal Sarcomas
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Pilot Study for Young Women's Intervention
- Status
- COMPLETED
- Phase
- NA
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2